CO2019011591A2 - Terapia de combinación para cáncer de próstata - Google Patents
Terapia de combinación para cáncer de próstataInfo
- Publication number
- CO2019011591A2 CO2019011591A2 CONC2019/0011591A CO2019011591A CO2019011591A2 CO 2019011591 A2 CO2019011591 A2 CO 2019011591A2 CO 2019011591 A CO2019011591 A CO 2019011591A CO 2019011591 A2 CO2019011591 A2 CO 2019011591A2
- Authority
- CO
- Colombia
- Prior art keywords
- prostate cancer
- combination therapy
- effective amount
- therapeutically effective
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019011591A2 true CO2019011591A2 (es) | 2020-02-28 |
Family
ID=62067858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0011591A CO2019011591A2 (es) | 2017-04-13 | 2019-10-18 | Terapia de combinación para cáncer de próstata |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| JP7442328B2 (ja) * | 2020-02-03 | 2024-03-04 | 株式会社三共 | 遊技機 |
| CN113546037B (zh) * | 2020-04-20 | 2024-12-27 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| WO2021224471A1 (en) * | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Pharmaceutical formulations of abiraterone acetate and niraparib |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| WO2023109758A1 (en) | 2021-12-15 | 2023-06-22 | Hunan Huize Biopharma S&T Co., Ltd | Abiraterone acetate-containing composition and application thereof |
| AU2023250030A1 (en) * | 2022-04-07 | 2024-11-07 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62034B1 (sr) | 2006-08-25 | 2021-07-30 | Janssen Oncology Inc | Kompozicije za lečenje raka |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0244A patent/JOP20190244A1/ar unknown
-
2018
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro not_active IP Right Cessation
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Ceased
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en not_active Ceased
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 IL IL269879A patent/IL269879B2/en unknown
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 UA UAA201911057A patent/UA129514C2/uk unknown
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 IL IL320452A patent/IL320452A/en unknown
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 SM SM20220467T patent/SMT202200467T1/it unknown
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 CN CN202411589875.XA patent/CN119235874A/zh active Pending
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 MY MYPI2023006196A patent/MY209010A/en unknown
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346A1/en active Pending
- 2024-08-09 US US18/799,339 patent/US20240398837A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011591A2 (es) | Terapia de combinación para cáncer de próstata | |
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| CL2009001011A1 (es) | Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa. | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| CO2021000923A2 (es) | Formulaciones de un inhibidor de axl/mer | |
| MX2017011237A (es) | Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides. | |
| MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
| PH12020550151A1 (en) | Methods of treating prostate cancer | |
| BR112022022590A2 (pt) | Formulações farmacêuticas de acetato de abiraterona e niraparibe | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2024012369A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. |